Acumen Hypotension Prediction Index (HPI) Feature Software vs TeraRecon Cardiovascular.Calcification.CT

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Acumen Hypotension Prediction Index (HPI) Feature Software

by Edwards Lifesciences

TeraRecon Cardiovascular.Calcification.CT

by Terarecon

AI Verdict

Tool A focuses on real-time predictive monitoring of hypotensive events using hemodynamic data to aid in proactive management within acute care settings. In contrast, Tool B is an imaging analysis tool that quantifies coronary artery calcification from CT scans for diagnostic and risk assessment purposes. While both fall under Cardiology AI, their distinct data inputs, clinical applications, and primary objectives make them adjacent rather than direct competitors.

Choose Acumen Hypotension Prediction Index (HPI) Feature Software if…

Choose Acumen Hypotension Prediction Index (HPI) Feature Software if your primary goal is real-time, proactive hemodynamic management to prevent hypotensive events in critically ill or surgical patients. This tool is ideal for clinicians who need early warnings and actionable insights into a patient's hemodynamic status to intervene before blood pressure drops significantly.

View Acumen Hypotension Prediction Index (HPI) Feature Software →

Choose TeraRecon Cardiovascular.Calcification.CT if…

Choose TeraRecon Cardiovascular.Calcification.CT if you require automated and precise analysis of CT images for coronary artery calcification scoring and cardiovascular risk assessment. This software is best suited for radiologists and cardiologists looking to efficiently quantify calcified plaques and support diagnostic decisions based on detailed calcium measurements.

View TeraRecon Cardiovascular.Calcification.CT →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Acumen Hypotension Prediction Index (HPI) Feature Software	TeraRecon Cardiovascular.Calcification.CT
Pricing	Contact vendor	Subscription-based
Deployment	Integrated into Edwards Lifesciences HemoSphere advanced monitoring platform.	Containerized application (SaMD), also available as SaaS within Eureka Clinical AI platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Acumen Hypotension Prediction Index (HPI) Feature Software

Tool A integrates directly into real-time patient monitoring with a clear 0-100 HPI score, smart alerts, and intuitive screens, making it highly actionable for clinicians in critical care settings. While Tool B automates complex image analysis, Tool A's immediate, proactive alerts for impending hypotensive events offer a distinct usability advantage for time-sensitive interventions.

Clinical Value

Acumen Hypotension Prediction Index (HPI) Feature Software

Tool A offers a demonstrated reduction in the incidence, duration, and severity of intraoperative hypotension, directly impacting patient safety and outcomes through proactive hemodynamic management. Tool B provides crucial quantitative data for cardiovascular risk assessment and treatment planning, but Tool A's proven ability to prevent acute adverse events highlights a more immediate and measurable clinical benefit.

Pricing & Value

TeraRecon Cardiovascular.Calcification.CT

Tool B offers a transparent subscription-based model with a single annual fee, providing clear budget predictability and flexibility for operational expenses. Tool A's pricing requires direct vendor contact, which lacks transparency and can make budgeting more challenging. Therefore, Tool B provides better clarity and predictability in its pricing structure.

Enterprise Readiness

Tie

Both tools demonstrate strong enterprise readiness, with explicit FDA clearance, HIPAA compliance, and Business Associate Agreement (BAA) availability. They are also deployed by established companies within existing clinical platforms, indicating robust integration capabilities and adherence to industry standards. It is difficult to distinguish a clear winner based on the provided information.

Innovation

Acumen Hypotension Prediction Index (HPI) Feature Software

Tool A represents a significant innovation by using machine learning for real-time predictive analysis of physiological waveforms to anticipate hypotensive events up to 15 minutes in advance. This proactive intervention capability moves beyond traditional reactive monitoring. While Tool B's automated image segmentation is also innovative, Tool A's predictive, real-time clinical decision support offers a higher degree of novelty and direct impact on acute patient management.

Support & Docs

Tie

The provided structured facts do not offer specific details regarding the support and documentation for either tool. Both companies are well-established in the healthcare technology sector, implying they likely offer comprehensive support and resources. Without further comparative information, it is not possible to definitively pick a winner.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Acumen Hypotension Prediction Index (HPI) Feature Software	TeraRecon Cardiovascular.Calcification.CT
Primary Function	Predictive monitoring tool that uses machine learning to detect and alert clinicians to the likelihood of a hypotensive event before it occurs.	AI-powered software that analyzes CT images to automatically detect and measure calcifications in the coronary arteries.
Company	Edwards Lifesciences	Terarecon
Target Specialties	Anesthesiology, Critical Care, Emergency Medicine	Cardiology, Cardiothoracic Surgery, Radiology
Key Analytical Output/Feature	Hypotension Prediction Index (HPI) parameter (0-100 score), Smart Alerts, Relationship View (preload, afterload, and contractility).	Automatic 3D segmentation of calcified plaques, mask for calcium scoring systems (Agatston score, volume, mean mass).
Input Data Type	Invasive (arterial line) and non-invasive (Acumen IQ cuff) monitoring (blood pressure waveforms).	CT images.
Predictive Capability	Predicts hypotension up to 15 minutes before an event.	Not specified

Videos

Demos, reviews, and walkthroughs featuring Acumen Hypotension Prediction Index (HPI) Feature Software and TeraRecon Cardiovascular.Calcification.CT.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into a physician's daily workflow and what is their primary clinical utility?

Acumen HPI is integrated into the Edwards Lifesciences HemoSphere advanced monitoring platform, providing real-time predictive alerts for hypotensive events up to 15 minutes before they occur. This aids anesthesiologists, critical care, and emergency medicine physicians in proactive hemodynamic management and improving patient outcomes. TeraRecon Cardiovascular.Calcification.CT analyzes CT images to automatically detect and measure coronary artery calcifications, outputting masks for calcium scoring systems. This supports cardiologists, cardiothoracic surgeons, and radiologists in risk stratification, diagnosis, and pre-operative evaluation.

What specific performance characteristics or clinical outcomes are associated with each tool's accuracy?

Acumen HPI uses machine learning algorithms for predictive analysis of blood pressure waveforms and has demonstrated a reduction in the incidence, duration, and severity of intraoperative hypotension. It has shown high sensitivity and specificity in predicting hypotension, with an AUC of 0.95 at 10 minutes before an event. TeraRecon Cardiovascular.Calcification.CT performs automatic 3D segmentation of calcified plaques in coronary arteries and supports precise Agatston score, volume, and mean mass measurements. It has demonstrated robust segmentation and classification performance, with mean accuracies exceeding 94% for Agatston categories.

What is the expected learning curve for physicians to become proficient in using each tool and interpreting its outputs?

Acumen HPI presents information through an HPI parameter (0-100 score), Smart Alerts, and a Relationship View screen, which provides insights into preload, afterload, and contractility. This structured presentation aims to simplify the interpretation of complex hemodynamic data for clinicians in acute care settings. TeraRecon Cardiovascular.Calcification.CT automates the detection and measurement of calcifications and outputs data for standard calcium scoring systems. Its clinician-centric design with intuitive workflows and zero-click centerline creation suggests a streamlined interpretation process for radiologists and cardiologists.

What are the key considerations for deploying these tools across multiple hospital sites or clinical environments?

As Acumen HPI is integrated into the Edwards Lifesciences HemoSphere advanced monitoring platform, multi-site deployment would involve standardizing and rolling out the HemoSphere infrastructure across different facilities. This ensures consistent predictive monitoring capabilities for hemodynamic management. TeraRecon Cardiovascular.Calcification.CT is offered as a containerized application (SaMD) and as SaaS within the Eureka Clinical AI platform. This deployment flexibility suggests it can be adapted to various IT environments for multi-site implementation, potentially leveraging cloud infrastructure.

What kind of audit-trail capabilities does each tool offer for tracking usage, alerts, or diagnostic interpretations?

The provided descriptions for Acumen HPI do not explicitly detail specific audit-trail features for tracking usage, alerts, or interventions. However, its role as a critical care monitoring tool suggests the presence of internal logging mechanisms for data integrity. The information for TeraRecon Cardiovascular.Calcification.CT does not specify audit-trail features for tracking image analysis or scoring outputs. As a medical device software, it would be expected to adhere to industry standards for data integrity and traceability.

Are customer references or case studies available to demonstrate the real-world impact and time-to-value of these tools?

The provided information for Acumen HPI mentions clinical studies demonstrating a reduction in intraoperative hypotension and improved patient outcomes, indicating available evidence of real-world impact. TeraRecon's website offers product tours and mentions customer experiences, suggesting that case studies or references may be available to illustrate the time-to-value and impact of Cardiovascular.Calcification.CT in clinical practice.